TZIELD DIN 02557347
Health Canada record
| Active ingredient(s) | TEPLIZUMAB 2 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | A10XX01 TEPLIZUMAB |
| Original market date | 20-Aug-2025 |
| Current status date | 20-Aug-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 35295 | 2025-05-05 | New Drug Submission (NDS) |